Protective effect of bicyclol on tetracycline-induced fatty liver in mice

被引:89
作者
Yu, Hong-Yan [1 ]
Wang, Bao-Lian [1 ]
Zhao, Jing [1 ]
Yao, Xiao-Min [1 ]
Gu, Yu [1 ]
Li, Yan [1 ]
机构
[1] Chinese Acad Med Sci, Inst Mat Med, Dept New Drug Dev, Beijing 100050, Peoples R China
关键词
NAFLD; Tetracycline; PPAR alpha; Mitochondrial dysfunction; Bicyclol; MITOCHONDRIAL RESPIRATORY-CHAIN; STEATOHEPATITIS; STEATOSIS; ACID; RAT; OXIDATION; DISEASE; PPAR; DYSFUNCTION; INHIBITION;
D O I
10.1016/j.tox.2009.04.058
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Peroxisome proliferators-activated receptor alpha (PPAR alpha) and oxidative stress are two important pathological factors in non-alcoholic fatty liver disease (NAFLD). Tetracycline-induced fatty liver was partly due to the disturbance of mitochondrial fatty acids beta-oxidation regulated by PPAR alpha. Bicyclol was found to protect against high fat diet-induced fatty liver through modulating PPAR alpha and clearing reactive oxygen species (ROS). The present study was performed to further investigate the effect of bicyclol on tetracycline-induced fatty liver and related mechanism in mice. Bicyclol (75, 150, 300 mg/kg) was given orally three times in two consecutive days. Tetracycline (200 mg/kg) was injected intraperitoneally 1 h after the last administration of bicyclol. Oxidative stress, mitochondrial function, PPAR alpha and its target genes were evaluated by biochemical and RT-PCR analysis. The activity of CYP4A was assessed by liquid chromatography/mass spectrometry (LC/MS) method. Bicyclol significantly protected against tetracycline-induced fatty liver by reducing the accumulation of hepatic lipids and elevation of serum aminotransferase. In addition, bicyclol remarkably alleviated the over-production of thiobarbituric acid-reactive substance. The reduced activity of mitochondrial respiratory chain (MRC) complexes I and IV and mitochondrial permeability transition (MPT) were also improved by bicyclol. Furthermore, bicyclol inhibited the decrease of PPAR alpha expression and its target genes, including long-chain acyl CoA dehydrogenase (LOAD), acetyl CoA oxidase (AOX) and CYP4A at mRNA and enzyme activity level. Bicyclol protected against tetracycline-induced fatty liver mainly through modulating the disturbance of PPAR alpha pathway and ameliorating mitochondrial function. (c) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:112 / 118
页数:7
相关论文
共 33 条
[1]
Nonalcoholic fatty liver disease [J].
Adams, LA ;
Angulo, P ;
Lindor, KD .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 172 (07) :899-905
[2]
[Anonymous], 2001, CHIN J NEW DRUGS
[3]
[Anonymous], ANAL BIOCHEM
[4]
ISOLATION OF PEROXISOMES FROM RAT-LIVER USING SUCROSE AND PERCOLL GRADIENTS [J].
APPELKVIST, EL ;
BRUNK, U ;
DALLNER, G .
JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, 1981, 5 (04) :203-217
[5]
Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition [J].
Cave, Matthew ;
Deaciuc, Ion ;
Mendez, Christian ;
Song, Zhenyuan ;
Joshi-Barve, Swati ;
Barve, Shirish ;
McClain, Craig .
JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2007, 18 (03) :184-195
[6]
Etiopathogenesis of nonalcoholic steatohepatitis [J].
Chitturi, S ;
Farrell, GC .
SEMINARS IN LIVER DISEASE, 2001, 21 (01) :27-41
[7]
TISSUE SULFHYDRYL GROUPS [J].
ELLMAN, GL .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1959, 82 (01) :70-77
[8]
INHIBITION OF THE MITOCHONDRIAL OXIDATION OF FATTY-ACIDS BY TETRACYCLINE IN MICE AND IN MAN - POSSIBLE ROLE IN MICROVESICULAR STEATOSIS INDUCED BY THIS ANTIBIOTIC [J].
FRENEAUX, E ;
LABBE, G ;
LETTERON, P ;
DINH, TL ;
DEGOTT, C ;
GENEVE, J ;
LARREY, D ;
PESSAYRE, D .
HEPATOLOGY, 1988, 8 (05) :1056-1062
[9]
Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice [J].
Garcia-Ruiz, Inmaculada ;
Rodriguez-Juan, Cristina ;
Diaz-Sanjuan, Teresa ;
Angel Martinez, Miguel ;
Munoz-Yague, Teresa ;
Solis-Herruzo, Jose A. .
HEPATOLOGY, 2007, 46 (02) :414-423
[10]
Nonalcoholic fatty liver disease: Pathogenesis and potential for nuclear receptors as therapeutic targets [J].
George, Jacob ;
Liddle, Christopher .
MOLECULAR PHARMACEUTICS, 2008, 5 (01) :49-59